Characterizing T cell responses to enzymatically modified beta cell neo-epitopes.
T cell
Type 1 diabetes (T1D)
at risk
citrullinated autoantigens
deamidated autoantigens
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
08
2022
accepted:
19
12
2022
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Previous studies verify the formation of enzymatically post-translationally modified (PTM) self-peptides and their preferred recognition by T cells in subjects with type 1 diabetes (T1D). However, questions remain about the relative prevalence of T cells that recognize PTM self-peptides derived from different antigens, their functional phenotypes, and whether their presence correlates with a specific disease endotype. To address this question, we identified a cohort of subjects with T1D who had diverse levels of residual beta cell function. Using previously developed HLA class II tetramer reagents, we enumerated T cells that recognize PTM GAD epitopes in the context of DRB1*04:01 or PTM IA2 epitopes in the context of DQB1*03:02 (DQ8). Consistent with prior studies, we observed higher overall frequencies and a greater proportion of memory T cells in subjects with T1D than in HLA matched controls. There were significantly higher numbers of GAD specific T cells than IA2 specific T cells in subjects with T1D. T cells specific for both groups of epitopes could be expanded from the peripheral blood of subjects with established T1D and at-risk subjects. Expanded neo-epitope specific T cells primarily produced interferon gamma in both groups, but a greater proportion of T cells were interferon gamma positive in subjects with T1D, including some poly-functional cells that also produced IL-4. Based on direct surface phenotyping, neo-epitope specific T cells exhibited diverse combinations of chemokine receptors. However, the largest proportion had markers associated with a Th1-like phenotype. Notably, DQ8 restricted responses to PTM IA2 were over-represented in subjects with lower residual beta cell function. Neo-epitope specific T cells were present in at-risk subjects, and those with multiple autoantibodies have higher interferon gamma to IL-4 ratios than those with single autoantibodies, suggesting a shift in polarization during progression. These results reinforce the relevance of PTM neo-epitopes in human disease and suggest that distinct responses to neo-antigens promote a more rapid decline in beta cell function.
Identifiants
pubmed: 36703975
doi: 10.3389/fimmu.2022.1015855
pmc: PMC9871889
doi:
Substances chimiques
Autoantibodies
0
Epitopes
0
Interferon-gamma
82115-62-6
Interleukin-4
207137-56-2
Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1015855Informations de copyright
Copyright © 2023 Nguyen, Arribas-Layton, Chow, Speake, Kwok, Hessner, Greenbaum and James.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Med. 2016 Dec;22(12):1482-1487
pubmed: 27798614
J Exp Med. 1999 May 17;189(10):1531-44
pubmed: 10330432
J Allergy Clin Immunol. 2010 Jun;125(6):1407-1409.e1
pubmed: 20513526
Diabetes. 2014 Jan;63(1):237-47
pubmed: 24089515
Nature. 2005 May 12;435(7039):220-3
pubmed: 15889095
PLoS One. 2014 Nov 18;9(11):e112882
pubmed: 25405480
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14840-5
pubmed: 25267644
PLoS One. 2013 Jun 05;8(6):e64632
pubmed: 23755131
PLoS Pathog. 2016 Jan 21;12(1):e1005375
pubmed: 26795118
Diabetes. 2018 Jul;67(7):1356-1368
pubmed: 29654212
Diabetes. 2018 Jun;67(6):1035-1042
pubmed: 29784651
Diabetes. 2008 Apr;57(4):1084-92
pubmed: 18252895
Nature. 2015 Apr 23;520(7548):558-62
pubmed: 25686607
Diabetes. 2012 Aug;61(8):2066-73
pubmed: 22688329
Science. 2015 Jan 23;347(6220):400-6
pubmed: 25477212
Diabetes. 2018 Nov;67(11):2337-2348
pubmed: 30348823
Diabetologia. 2014 Jan;57(1):187-91
pubmed: 24121625
Curr Diab Rep. 2015 Nov;15(11):90
pubmed: 26370701
J Immunol. 2004 May 15;172(10):5967-72
pubmed: 15128778
J Exp Med. 2005 Nov 7;202(9):1191-7
pubmed: 16260488
J Immunol. 2007 Jun 1;178(11):7032-41
pubmed: 17513752
Science. 1995 May 26;268(5214):1185-8
pubmed: 7761837
Nat Immunol. 2007 Jun;8(6):639-46
pubmed: 17486092
Diabetes. 2014 Feb;63(2):739-48
pubmed: 24089509
Nat Med. 2017 Apr;23(4):501-507
pubmed: 28263308
Diabetes. 2014 Sep;63(9):3033-40
pubmed: 24705406